纤维蛋白原

FGEN NASDAQ
42.27
-1.27
-2.92%
盘后: 42.27 0 0.00% 16:30 06/25 EDT
开盘
43.75
昨收
43.54
最高
43.86
最低
41.88
成交量
56.97万
成交均量(3M)
87.09万
52周最高
68.55
52周最低
33.51
换手率
0.66%
市值
36.45亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供纤维蛋白原 FGEN股票价格,纤维蛋白原股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
展开 >

最近浏览

名称
价格
涨跌幅